A comparison study of prabotulinumtoxinA vs onabotulinumtoxinA in myostatin‐deficient mice with muscle hypertrophy

Botulinum toxin A (BoNT‐A) is used clinically for various muscle disorders and acts by preventing the release of the neurotransmitter acetylcholine into the synapse space. Here, we compared the efficacy of prabotulinumtoxinA (PRA) and onabotulinumtoxinA (ONA) for the reduction in hypertrophy in myos...

Full description

Saved in:
Bibliographic Details
Published in:Basic & clinical pharmacology & toxicology 2019-04, Vol.124 (4), p.491-499
Main Authors: Bak, Dong‐ho, Choi, Mi Ji, Lee, Esther, Kwon, Tae‐Rin, Kim, Jong Hwan, Nam, Sang‐Hyun, Kim, Kyoung‐Yun, Ahn, Seung Won, Mun, Seog‐Kyun, Na, Jungtae, Kim, Beom Joon
Format: Article
Language:English
Subjects:
Acetylcholine
Animals
Atrophy
Botulinum toxin
Botulinum toxin type A
Botulinum Toxins - administration & dosage
Botulinum Toxins - pharmacology
Botulinum Toxins, Type A - administration & dosage
Botulinum Toxins, Type A - pharmacology
Denervation
Disease Models, Animal
Dose-Response Relationship, Drug
Dystrophin
Eutrophication
Hindlimb
Hypertrophy
Hypertrophy - drug therapy
Hypertrophy - physiopathology
Male
Medical treatment
Mice
Mice, Inbred C57BL
Mice, Knockout
Muscle, Skeletal - pathology
Muscles
Muscular Diseases - drug therapy
Muscular Diseases - physiopathology
Myostatin
Myostatin - genetics
Nerve conduction
Neuromuscular Agents - administration & dosage
Neuromuscular Agents - pharmacology
Sciatic nerve
Skeletal muscle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Botulinum toxin A (BoNT‐A) is used clinically for various muscle disorders and acts by preventing the release of the neurotransmitter acetylcholine into the synapse space. Here, we compared the efficacy of prabotulinumtoxinA (PRA) and onabotulinumtoxinA (ONA) for the reduction in hypertrophy in myostatin‐deficient (Mstn−/−) mice. Two different BoNT‐A products (2.5, 10 and 25 U/kg) were injected to paralyse the hindlimb for 2 months, after which sciatic nerve conduction study, 3D micro‐CT, haematoxylin and eosin (H&E) and dystrophin staining were conducted. Administration of BoNT‐A products induced denervation‐mediated atrophy and alleviated muscle hypertrophy generated in Mstn−/− mice. The present study revealed that each BoNT‐A regulates skeletal muscle size, myofibre number and myofibre diameter in Mstn−/− mice. The potential applicability of BoNT‐A for the treatment of rare muscle hypertrophic diseases was demonstrated. Compared with ONA, PRA had a comparable ability to act in the local area.
ISSN:1742-7835
1742-7843
DOI:10.1111/bcpt.13151